Gene Therapy of Cancer Using an AAV Serotype 2-Mediated Gene Delivery System Containing Different Combinations of Antisense VEGF-A cDNA, Truncated Soluble VEGFR-1, and Truncated Soluble VEGFR-2 cDNA

2005 ◽  
Vol 28 (6) ◽  
pp. 610
Author(s):  
Keerang Park ◽  
Seock-Yeon Hwang ◽  
Young-Hwa Cho ◽  
Youn-Ju Kim ◽  
Young-Ill Lee ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Delivery ◽  
Delivery System ◽  
Gene Delivery System

scholarly journals Next Generation Delivery System for Proteins and Genes of Therapeutic Purpose: Why and How?

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Ashish Ranjan Sharma ◽  
Shyamal Kumar Kundu ◽  
Ju-Suk Nam ◽  
Garima Sharma ◽  
C. George Priya Doss ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Delivery ◽  
Delivery System ◽  
Delivery Systems ◽  
Therapeutic Protein ◽  
Gene Delivery System ◽  
Next Generation ◽  
Therapeutic Purpose ◽  
Detailed Explanation ◽  
Or Gene

Proteins and genes of therapeutic interests in conjunction with different delivery systems are growing towards new heights. “Next generation delivery systems” may provide more efficient platform for delivery of proteins and genes. In the present review, snapshots about the benefits of proteins or gene therapy, general procedures for therapeutic protein or gene delivery system, and different next generation delivery system such as liposome, PEGylation, HESylation, and nanoparticle based delivery have been depicted with their detailed explanation.

PREPARATION OF CALCIUM PHOSPHATE NANOPARTICLES AS NON-VIRAL VECTORS FOR GENE DELIVERY SYSTEM

2017 ◽  
Vol 29 (04) ◽  
pp. 1750027 ◽  
Author(s):  
Ko-Chung Yen ◽  
I-Hua Chen ◽  
Feng-Huei Lin
Keyword(s):  
Gene Therapy ◽  
Calcium Phosphate ◽  
Gene Delivery ◽  
Delivery System ◽  
Viral Vectors ◽  
Fluorescent Protein ◽  
Molar Ratio ◽  
Gene Delivery System ◽  
Calcium Phosphate Nanoparticles

A major aim of gene therapy is the efficient and specific delivery of therapeutic gene into the desired target tissues. Development of reliable vectors is a major challenge in gene therapy. The aim of this study is to develop calcium phosphate nanoparticles as novel non-viral vectors for the gene delivery system. Calcium phosphate nanoparticles were prepared by water-in-oil microemulsion method with a water to surfactant molar ratio, Wo [Formula: see text] 2–10. This paper studies the design and synthesis of ultra-low size, highly monodispersed DNA doped calcium phosphate nanoparticles of size around 100[Formula: see text]nm in diameter. The structure of DNA-calcium phosphate nanocomplex observed by TEM was displayed as a shell-like structure. This study used pEGFP as a reporter gene. The encapsulating efficiency to encapsulate DNA inside the nanoparticles was greater than 80%. In the MTT test, both calcium phosphate nanoparticles and DNA-calcium phosphate nanocomplex have no negative effect for 293T cells. By gel electrophoresis of free and entrapped pEGFP DNA, the DNA encapsulated inside the nanoparticles was protected from the external DNaseI environment. In vitro transfection studies in 293T cell-line, the DNA-calcium phosphate nanocomplex could be used safely to transfer the encapsulated DNA into the 293T cells and expression green fluorescent protein. The characteristic of DNA-calcium phosphate nanocomplex to deliver DNA belongs to slow release. The property of DNA-calcium phosphate nanocomplex was fit in the requirement of non-viral vectors for the gene delivery system.

Gene Transfer Using Nonviral Delivery Systems

2006 ◽  
Vol 26 (6) ◽  
pp. 633-640 ◽  
Author(s):  
Masanobu Miyazaki ◽  
Yoko Obata ◽  
Katsushige Abe ◽  
Akira Furusu ◽  
Takehiko Koji ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Peritoneal Dialysis ◽  
Gene Transfer ◽  
Gene Delivery ◽  
Delivery System ◽  
Viral Vectors ◽  
Nonviral Vectors ◽  
Gene Delivery System ◽  
Peritoneal Membrane ◽  
Peritoneal Function

In peritoneal dialysis, loss of peritoneal function is a major factor in treatment failure. The alterations in peritoneal function are related to structural changes in the peritoneal membrane, including peritoneal sclerosis with increased extracellular matrix. Although peritoneal sclerosis is considered reversible to some extent through peritoneal rest, which improves peritoneal function and facilitates morphological changes, there has been no therapeutic intervention and no drug against the development and progression of peritoneal sclerosis. Using recent biotechnological advances in genetic engineering, a strategy based on genetic modification of the peritoneal membrane could be a potential therapeutic maneuver against peritoneal sclerosis and peritoneal membrane failure. Before this gene therapy may be applied clinically, a safe and effective gene delivery system as well as the selection of a gene therapy method must be established. There are presently two kinds of gene transfer vectors: viral and nonviral. Viral vectors are used mainly as a gene delivery system in the field of continuous ambulatory peritoneal dialysis research; however, they have several problems such as immunogenicity and toxicity. On the other hand, nonviral vectors have several advantages over viral vectors. We review here gene transfer using nonviral vector systems in the peritoneum: electroporation, liposomes, and cationized gelatin microspheres. In the field of peritoneal dialysis, gene therapy research using nonviral vectors is presently limited. Improvement in delivery methods together with an intelligent design of targeted genes has brought about large degrees of enhancement in the efficiency, specificity, and temporal control of nonviral vectors.

scholarly journals Recent Trends of Polymer Mediated Liposomal Gene Delivery System

2014 ◽  
Vol 2014 ◽  
pp. 1-15 ◽  
Author(s):  
Shyamal Kumar Kundu ◽  
Ashish Ranjan Sharma ◽  
Sang-Soo Lee ◽  
Garima Sharma ◽  
C. George Priya Doss ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Delivery ◽  
Delivery System ◽  
Genetic Diseases ◽  
Delivery Systems ◽  
Gene Delivery System ◽  
Liposome Formulation ◽  
Recent Trends ◽  
Delivery Route ◽  
Future Direction

Advancement in the gene delivery system have resulted in clinical successes in gene therapy for patients with several genetic diseases, such as immunodeficiency diseases, X-linked adrenoleukodystrophy (X-ALD) blindness, thalassemia, and many more. Among various delivery systems, liposomal mediated gene delivery route is offering great promises for gene therapy. This review is an attempt to depict a portrait about the polymer based liposomal gene delivery systems and their future applications. Herein, we have discussed in detail the characteristics of liposome, importance of polymer for liposome formulation, gene delivery, and future direction of liposome based gene delivery as a whole.

scholarly journals Antisense Gene Therapy of Brain Cancer with an Artificial Virus Gene Delivery System

2002 ◽  
Vol 6 (1) ◽  
pp. 67-72 ◽  
Author(s):  
Yun Zhang ◽  
Chunni Zhu ◽  
William M. Pardridge
Keyword(s):  
Gene Therapy ◽  
Gene Delivery ◽  
Delivery System ◽  
Brain Cancer ◽  
Gene Delivery System ◽  
Antisense Gene ◽  
Virus Gene ◽  
Artificial Virus

Novel Gene Delivery System of Sendai Virus Transduced Human Peripheral Monocytes.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5482-5482
Author(s):  
Tomoko Tanaka ◽  
Ryo Kurita ◽  
Kashiya Takasugi ◽  
Takafumi Nakamura ◽  
Makoto Inoue ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Gene Delivery ◽  
Delivery System ◽  
Sendai Virus ◽  
Transduction Efficiency ◽  
Gene Delivery System ◽  
Gene Transduction ◽  
Novel Gene

Abstract Extensive monocytes extravasation is seen in infection sites, inflamed tissue and tumor tissues and exhibit a tissue-specific range of functions including phagocytosis, antigen presentation to T cells, and the release of a wide array of cytokines, chemokines, enzymes and nitrogen species. As monocytes have natural tropism to such tissues in each disease condition, these cells can be used as novel gene delivery system to cure the condition. On the other hand, as monocytes are quiescent cells, available gene transfer vectors are limited. Sendai virus (SeV) is a negative-strand RNA virus and has recently been used for the gene therapy vectors, SeV vectors (SeVV), for somatic gene therapy. This vector does not have potential of stable transformation of target cells because they generate no DNA intermediates and therefore are unable to integrate. Also, SeVV has been shown to ensure efficient expression of foreign genes in various types of tissues and can be used for gene transfer into monocytes. We first of all studied the gene transduction efficiency of SeVV into human peripheral blood CD 14 positive monocytes using GFP gene as a marker. About 82% of monocytes became GFP positive, whereas only 23% of lymphocytes and 1.8% of granulocytes became positive. The transduction efficiency was peaked at M.O.I.=1. The expression level was at least preserved for 24 hours in vitro. To do the in vivo preclinical experiments, we also transduced cDNA of GFP and GDNF (glial cell line-derived neurotrophic factor) into the peripheral monocytes of Macaca fascicularis monkey and high level expression of these genes were obtained. In vitro monocyte function after gene transduction are now under investigation. SeVV is considered to be promising gene transfer vector for primate monocytes.

A RAGE-antagonist peptide potentiates polymeric micelle-mediated intracellular delivery of plasmid DNA for acute lung injury gene therapy

Nanoscale ◽  
2020 ◽  
Vol 12 (25) ◽  
pp. 13606-13617
Author(s):  
Chunxian Piao ◽  
Chuanyu Zhuang ◽  
Myoungjee Choi ◽  
Junkyu Ha ◽  
Minhyung Lee
Keyword(s):  
Gene Therapy ◽  
Acute Lung Injury ◽  
Gene Delivery ◽  
Lung Injury ◽  
Delivery System ◽  
Plasmid Dna ◽  
Intracellular Delivery ◽  
Polymeric Micelle ◽  
Gene Delivery System

Pulmonary gene delivery system was developed based on RAGE-antagonist peptide and dexamethasone-conjugated polyamidoamine.

Sign in / Sign up

Export Citation Format

Share Document